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I. INTRODUCTION
Antibiotic resistant “superbugs” are a concerning public health threat in the
United States and worldwide. Antibiotic resistance refers to infections that are
resistant to current antibiotics.2 The rise of these superbugs requires innovative
public health responses to these emerging microbial threats. This article seeks to
advocate for an innovative, twenty-first century solution using traditional health
department responses: tracking, monitoring, and surveillance. These activities—
which can be conducted through the existing infrastructure of Prescription Drug
Monitoring Programs (PDMP)—would allow states, counties, and localities to
track and monitor antimicrobial resistance.
II. ANTIBIOTICS AND RESISTANCE
Antibiotic resistance presents a complex multifaceted problem which
requires groundbreaking solutions. To understand the underlying issues, this
article begins by providing background on antibiotics and the rise of antibiotic
resistant bacteria, followed by an overview of the existing federal legal landscape
in this area.3 Next, this article looks at the historical goals and functions of State
health departments regarding surveillance of emerging diseases.4 Then, this
article seeks to explain the existing infrastructure of PDMPs and innovative uses
of these programs.5

2. Antibiotic Prescribing & Use in Doctor’s Offices: Antibiotic Resistance Q&As, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/antibiotic-use/community/about/antibioticresistance-faqs.html (Aug. 23, 2021). “Antibiotic resistance happens when the germs no longer respond
to the antibiotics designed to kill them. That means the germs are not killed and continue to grow . . .
[A]ntibiotic-resistant germs are difficult, and sometimes impossible, to treat.” Id.
3. See infra Parts II.A–C.
4. See infra Part II.D.
5. See infra Parts II.E–F.
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A. Antibiotics: Past to Present
The modern era of antibiotics began in 1928 with Alexander Fleming’s
discovery of penicillin.6 Even after this momentous discovery, by the 1950s,
penicillin resistant infections began to emerge.7 We now see antibiotic resistance
in almost all known antibiotics.8 In response to this problem, various new
antibiotics were introduced from the 1960s through the early 1980s. Now,
however, fewer new antibiotics are being introduced.9 Since the 1970s, no new
antibiotic classes have been discovered.10 Major pharmaceutical companies have
reduced their antibiotic development because antibiotics are curative and often
not used for chronic conditions and are therefore less profitable than other
pharmaceuticals innovations.11 Further contributing to lack of profitability is that
the emerging best practice is to hold a new antibiotic in reserve for only severely
resistant cases.12 The World Health Organization (WHO) has classified
antibiotics in three groups: access, watch, and reserve.13 This classification
serves as guidance on which antibiotics should be used day-to-day (access),
which ones should be used cautiously (watch), and which ones should be used
only as the last resort (reserve).14 Even with the emerging problem of resistance,
antibiotics play a pivotal role in modern medicine and remain important in
treating infections which were once considered deadly.15

6. C. Lee Ventola, The Antibiotic Resistance Crisis: Part 1: Cases and Threats, 40 PHARMACY &
THERAPEUTICS 277, 277 (2015).
7. Id.
8. Id.
9. Id. at 278.
10. Rustam I. Aminov, A Brief History of the Antibiotic Era: Lessons Learned and Challenges for
the Future, FRONTIERS MICROBIOLOGY, Dec. 8, 2010, at 1, 3. Typically, antibiotics are classified by their
chemical structure. Antibiotic Resistance Patient Safety Atlas: Outpatient Antibiotic Prescription Data,
CTRS. FOR DISEASE CONTROL & PREVENTION, https://arpsp.cdc.gov/resources/OAU-Antibiotic-ClassDefinitions.pdf (last visited Feb. 4, 2022). Some antibiotics kill bacteria, while others keep the bacteria
from multiplying. Id. For example, “[c]ephalosporins kill bacteria by preventing formation of the bacterial
cell wall” while “[f]luoroquinolones kill bacteria by keeping bacteria from making DNA.” Id.
11. Ventola, supra note 6, at 279.
12. Id. at 279–80.
13. WORLD HEALTH ORG., EXECUTIVE SUMMARY: THE SELECTION AND USE OF ESSENTIAL
MEDICINES 1 (2017).
14. Id. at 2–4; see also Ariana Eunjung Cha, WHO Creates Controversial ‘Reserve’ List of
Antibiotics for Superbug Threats, WASH. POST (June 6, 2017), https://www.washingtonpost.com/news/toyour-health/wp/2017/06/06/who-creates-controversial-reserve-list-of-antibiotics-in-new-response-tosuperbug-threats/ (explaining the three antibiotic categories and providing a brief description of each).
15. See Ventola, supra note 6, at 278 (“Antibiotics have also helped to extend expected life spans by
changing the outcome of bacterial infections. In 1920, people in the U.S. were expected to live to only be
56.4 years old; now, however, the average U.S. life span is nearly 80 years.”).
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B. Antibiotic Resistant “Superbugs”

Antibiotic resistant bacteria are considered by the WHO to be “one of the
biggest threats to global health, food security, and development.”16 The Centers
for Disease Control and Prevention (CDC) views antibiotic resistance as one of
the biggest modern public health challenges.17 Each year in the United States,
over 2.8 million people contract an antibiotic-resistant infection, and “[m]ore
than 35,000 people die.”18 Alexander Fleming, upon winning the Nobel Prize for
his discovery of penicillin, cautioned of the dangers of misuse of his antibiotic
which could lead to organisms that resist penicillin.19 Currently, “methicillinresistant Staphylococcus Aures (MRSA), kills more Americans every year than
emphysema, HIV/AIDS, Parkinson’s disease, and homicide combined.”20 While
extremely difficult to calculate the total economic cost of these infections,
estimates indicate the cost could be as high as $20 billion a year in direct
healthcare related costs and additional costs to society for loss of productivity as
high as $35 billion a year.21 Antibiotic resistance has caused devastation for
many individuals and families including: nine year-old Kenna who faced
necrotizing pneumonia, a heart valve infection, an abscess in her thigh, and ten
days on a ventilator from a MRSA infection; fifty seven year-old George who
faced six surgeries related to an infection resistant to virtually every antibiotic;
and eleven year-old Addie who spent five months in the hospital, three months
on a machine which circulated her blood and added oxygen to it, and ultimately
required a double lung transplant due to a resistant infection.22
16. Antibiotic Resistance, WORLD HEALTH ORG. (July 31, 2020), https://www.who.int/newsroom/fact-sheets/detail/antibiotic-resistance.
17. Antibiotic/Antimicrobial Resistance, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/drugresistance/about.html (Dec. 13, 2021).
18. Id.
19. Cory Fox, Resisting Antibiotic Resistance: Legal Strategies to Maintain Man’s Dominion Over
Microbes, 12 HOUS. J. HEALTH L. & POL’Y 35, 37–38 (2011).
20. Erin LaMontagne, Comment, Off-Label Promotion, the First Amendment, and Practically
Addressing Antibiotic Resistance, 51 CAL. W. L. REV. 293, 295 (2015) (citing Infectious Disease Soc’y
of Am., Combating Antimicrobial Resistance: Policy Recommendations to Save Lives, 52 (Supp. 5) CLIN.
INFECTIOUS DISEASES S397–S428, S397 (2011)).
21. CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 11; see also Ventola, supra note 6, at 283
(explaining that “the medical cost per patient with an antibiotic resistant infection range[s] from $18,588
to $29,069.”).
22. Patient Stories: The Faces of Antimicrobial Resistance, INFECTIOUS DISEASE SOC’Y OF AM.,
https://www.idsociety.org/public-health/patient-stories/patient-stories/ (last visited Feb. 13, 2022);
Patient Stories: Kenna Van Kirk, INFECTIOUS DISEASE SOC’Y OF AM., https://www.idsociety.org/publichealth/patient-stories/kenna-van-kirk/ (last visited Feb. 13, 2022); Patient Stories: George Semakula,
INFECTIOUS DISEASE SOC’Y OF AM., https://www.idsociety.org/public-health/patient-stories/georgesemakula/ (last visited Feb. 13, 2022); Patient Stories: Addie Rerecich, INFECTIOUS DISEASE SOC’Y OF
AM., https://www.idsociety.org/public-health/patient-stories/addie-rerecich/ (last visited Feb. 13, 2022).
For further discussion, see INFECTIOUS DISEASE SOC’Y OF AM., FACES OF ANTIMICROBIAL RESISTANCE,
https://www.idsociety.org/globalassets/bb-complex-pages/pdf/foar-report-1-up-final.pdf
(describing
other individuals whose stories demonstrate the urgent need to combat antimicrobial resistance).
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While antibiotics have saved countless lives since their discovery in the
1940s, any use of antibiotics can also result in antibiotic resistance.23 While
antibiotic resistance cannot be attributed to a single cause, there are significant
human-caused factors that contribute to their resistance, including: (1) overuse
through over-prescription, (2) misuse through failure to complete the course of
treatment, (3) failure to contain antibiotic-resistant infections in healthcare
settings, (4) factory farming and sub-therapeutic use in meat products, and (5)
barriers to pharmaceutical innovation.24 As such, “[w]hile superbugs are a
frightening reminder of the adaptability and ingenuity of microorganisms, they
are also the direct result of mankind’s chronic misuse and persistent overuse of
antibiotics.”25 Since antibiotic resistance is a complex, multifaceted issue, some
of these factors are outside the scope of this article, which focuses on antibiotic
misuse and overuse.26
Antibiotic misuses involves two distinct sub-sets of activities: (1) when an
antibiotic is properly prescribed by a clinician and then is not taken as prescribed
or completed by the patient, and (2) when an antibiotic is improperly prescribed
by a clinician.27 Antibiotic overuse occurs when stronger, broad-spectrum
antibiotics are used to treat an infection that could be treated with a much weaker,
narrow-spectrum antibiotic.28 A strong correlation exists between the level of
antibiotic resistant infections and the level of antibiotic use.29 The magnitude of
the problem becomes apparent through the CDC’s estimation that thirty percent
of all antibiotics prescribed are for conditions that do not require their use.30 The
CDC has also found that urgent care facilities are the most frequent prescribers
of unnecessary antibiotics.31 In some states, there are more antibiotics prescribed
per year than there are people.32 To further understand the complexity of
23. CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 41.
24. Donna Hanrahan, Combatting Resistance: Federal Efforts to Reduce Overuse, Curb Misuse, and
Incentive the Development of Antibiotic Drugs, 26 ANNALS HEALTH L. 67, 70–71 (2017).
25. Fox, supra note 19, at 36.
26. See id. at 68 (explaining that the article addresses antibiotic resistance and makes
recommendations to reduce overuse, misuse, and encourage novel antibiotic drug development).
27. LaMontagne, supra note 20, at 303–04.
28. Id. at 304. Antibiotics include a range of spectrums: broad spectrum, intermediate spectrum, or
narrow spectrum. Antibiotic Resistance Learning Site: Spectrum of Activity, UNIV. OF MINN.
https://amrls.umn.edu/pharmacology (last visited Jan. 28, 2022). As the name suggests, a broad spectrum
antibiotic can work against a variety of bacterium. Id. In contrast, narrow spectrum antibiotics are typically
only effective against specific microorganisms. Id.
29. Aminov, supra note 10, at 4.
30. CTRS. FOR DISEASE CONTROL & PREVENTION, 2018 UPDATE ANTIBIOTIC USE IN THE UNITED
STATES PROGRESS AND OPPORTUNITIES 3 (2019), https://www.cdc.gov/antibiotic-use/stewardshipreport/pdf/stewardship-report-2018-508.pdf [hereinafter CDC, 2018 UPDATE].
31. Id. at 5. For example, providers in urgent care settings prescribe antibiotics unnecessarily in forty
six percent of the respiratory infections they treat. Id. Additionally, urgent cares also have the largest
percentage for visits resulting in an antibiotic prescription. Id.
32. Ventola, supra note 6, at 278.
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antibiotics and their governance it is important to acknowledge the existing legal
landscape within the United States.
C. Existing Legal Landscape
Within the United States, powers are separated between the state and
federal governments.33 While the United States has a system of federalism,
however, “[t]here is no bright line separating federal and state authorities. In
reality, governments’ respective powers have historically overlapped, especially
in areas like public health.”34 Antibiotic resistance can also implicate
international concerns which further blurs the lines between state and federal
responsibility.35 Traditionally, however, antibiotic resistance has been largely
monitored by federal agencies due to their greater institutional competencies.
1. Existing Federal Law Combatting Antibiotic Resistance
While various congressional proposals have been introduced to address
antibiotic resistance, these proposals largely have failed.36 Nevertheless, on
September 18, 2014, President Obama issued Executive Order 13676 which
sought to address antibiotic resistance.37 Among other things, the Executive
Order established antibiotic-resistant bacteria as a national security priority and
created a Task Force for Combating Antibiotic Resistant Bacteria, which
endeavored to improve antibiotic stewardship, strengthen national surveillance,
and promote new antibiotic development and international cooperation.38
Alongside the Executive Order, the United States National Strategy for
Combating Antibiotic-Resistant Bacteria was released.39 While there is limited
codified law, various agencies have begun to promulgate regulations and engage
in activities designed to combat antibiotic resistance. For example, the Federal
Health and Human Services’ Office of the Assistant Secretary for Preparedness
and Response focuses on the national security threat caused by antibiotic33. JAMES G. HODGE, JR., PUBLIC HEALTH LAW IN A NUTSHELL, 36–37 (4th ed. 2022).
34. Id.
35. See Antibiotic Resistance, supra note 16 (outlining the severe impact antibiotic resistance has on
global health, food security, and the healthcare system).
36. Andrew Geltman, Comment, Defusing the Bug Bomb: Legal Strategies to Combat Antibiotic
Resistant Infections, 18 J. HEALTH CARE L. & POL’Y 115, 117 n.18 (2015).
37. Off. of the Press Sec., Executive Order—Combating Antibiotic-Resistant Bacteria, WHITE
HOUSE: PRESIDENT BARACK OBAMA (Sept. 18, 2014), https://obamawhitehouse.archives.gov/the-pressoffice/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria.
38. Id.
39. Antibiotic/Antimicrobial Resistance: National Strategy, CTRS. FOR DISEASE CONTROL &
PREVENTION (Sept. 2014), https://www.cdc.gov/drugresistance/us-activities/national-strategy.html. The
national strategy outlines five goals which include: (1) slowing and preventing the spread of resistant
bacteria and infections, (2) strengthening surveillance efforts, (3) advancing development of diagnostic
testing for identification of resistant bacteria, (4) accelerating research and development for new
antibiotics, other therapeutics, and vaccines, and (5) improving international collaboration. Id.
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resistance.40 The remainder of Part II.C.1. will highlight the work of the two
Federal agencies who are most closely involved in this issue: The CDC and The
Food and Drug Administration (FDA).
a. Efforts by the CDC
The CDC is tasked with being “the lead agency for prevention, health data,
epidemic investigation, and public health measures aimed at disease control and
prevention.”41 The CDC seeks to combat antibiotic resistance with various
programs and initiatives.42 In fiscal year 2016, Congress appropriated $160
million to the CDC to fight antibiotic resistance with an additional $163 million
and $168 million provided in fiscal years 2017 and 2018, respectively.43 Some
of the programs administered by the CDC include: the AR Solutions Initiative;
an antibiotic stewardship program; the National Healthcare Safety Network
(NHSN); and other tracking and surveillance programs.44
i. AR Solutions Initiative
The AR Solutions Initiative is a CDC program that seeks to empower the
country to adequately respond to the emerging threat of antibiotic resistance.45
In addition, the “[i]nitiative invests in national infrastructure to detect, respond,
contain, and prevent resistant infections across healthcare settings, food, and
communities.”46 The AR Solutions Initiative has also established the AR Lab
Network which is a network of CDC labs that have expanded the testing capacity
of all state and local health departments.47 This expanded testing capacity fills
data gaps and allows better-informed responses to best determine treatment for
emerging resistant bacteria.48 Additional functions of the AR Lab Network
include rapid detection of antibiotic resistant infections to inform the local

40. Fight Against Superbugs Crucial to America’s Biodefense, PEW CHARITABLE TRS. (Feb. 1,
2019), https://www.pewtrusts.org/en/research-and-analysis/articles/2019/02/01/fight-against-superbugscrucial-to-americas-biodefense.
41. SARAH E. WILENSKY & JOEL B. TEITELBAUM, ESSENTIALS OF HEALTH POLICY AND LAW 88 (4th
ed. 2019).
42. See generally Antibiotic/Antimicrobial Resistance, supra note 17 (identifying eight key resources
and programs within the CDC that combat antibiotic resistance).
43. Antibiotic/Antimicrobial Resistance: What CDC is Doing: AR Solutions Initiative, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/drugresistance/solutions-initiative/index.html
(March 2, 2022) [hereinafter Antibiotic/Antimicrobial Resistance: What CDC is Doing].
44. Id.; see also CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 39–40 (outlining the serious health
threat antimicrobial resistance has on public health).
45. CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 39–40.
46. Antibiotic/Antimicrobial Resistance: What CDC is Doing, supra note 43.
47. Fighting Antibiotic Resistance, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/ncezid/pdf/two-pagers/NCEZID-antibiotic-resistance-2pgr-H.pdf (last visited Apr.
17, 2022).
48. Id.
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response teams, DNA sequencing, and the use of data to drive infection
prevention.49
ii. CDC Antibiotic Stewardship
The CDC also administers a guidance program for medical providers on
how they should prescribe and use antibiotics.50 Changing the way antibiotics
are used can drastically slow the spread of antibiotic resistance.51 Antibiotic
stewardship refers to the promotion of the correct use of antibiotics, a reduction
in resistance, and a decrease in the spread of resistant infections.52 The CDC
identifies the four core elements of antibiotic as: (1) commitment, (2) action for
policy and practice, (3) tracking/reporting, and (4) education.53 Through this
initiative, the CDC seeks to maximize the benefit of antibiotics while minimizing
harm to individuals and the public through its various educational, tracking, and
antibiotic stewardship programs that seek to educate providers and individuals
regarding the correct use of antibiotics.54
iii. CDC’s National Healthcare Safety Network
The National Healthcare Safety Network is an important CDC tracking tool
that collects and tracks data on resistant infections that occur in health care
facilities.55 NHSN allows for facility-specific tracking that can assist individual
facilities in combatting these infections and choosing the right antibiotics in the
future.56 Unfortunately, this tracking only focuses on healthcare-associated
infections and does not provide data for community-associated infections.57
Nevertheless, “NHSN provides facilities, states, regions, and the nation with data
needed to identify problem areas, measure progress of prevention efforts, and
49. Lab Capacity in Action to Fight Antibiotic Resistance, CTRS. FOR DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/drugresistance/solutions-initiative/ar-lab-network.html (last visited
Nov. 23, 2021).
50. See Core Elements of Antibiotic Stewardship, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/antibiotic-use/coreelements/index.html#:~:text=Antibiotic%20stewardship%20is%20the%20effort,use%2C%20and%20co
mbat%20antibiotic%20resistance (Apr. 7, 2021) (providing guidance relating to core elements and
implementation of antibiotic stewardship programs in various healthcare settings including: hospitals,
outpatient centers, nursing homes, small and critical access hospitals, and resource-limited settings).
51. CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 31.
52. CTRS. FOR MEDICARE & MEDICAID SERVS., A FIELD GUIDE TO ANTIBIOTIC STEWARDSHIP IN
OUTPATIENT SETTINGS 3 (2018).
53. CTRS. FOR DISEASE CONTROL & PREVENTION, THE CORE ELEMENTS OF OUTPATIENT
ANTIBIOTIC STEWARDSHIP 15, https://www.cdc.gov/antibiotic-use/community/pdfs/16_268900-A_Core
ElementsOutpatient_508.pdf [hereinafter CDC, THE CORE ELEMENTS].
54. Id. at 6.
55. CDC, ANTIBIOTIC RESISTANCE, supra note 1, at 40.
56. Id.
57. National Healthcare Safety Network (NHSN): About NHSN, CTRS. FOR DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/nhsn/about-nhsn/index.html (Jan. 25, 2021).
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ultimately eliminate healthcare-associated infections.”58 For fiscal year 2020,
Congress has provided $21 million to the CDC for NHSN to increase hospital
reporting of antibiotic use and resistance.59 The Centers for Medicare and
Medicaid Services (CMS) has also made certain incentive-based payments
contingent on reporting these measures to the CDC.60 Overall, the CDC has
found that tracking and reporting clinician antibiotic prescribing “can guide
changes in practice and can be used to assess progress in antibiotic
prescribing.”61
b. Efforts by the FDA
The FDA is another pivotal player in combatting antibiotic resistance.62 The
FDA is committed to addressing antibiotic resistance through the following
strategies: (1) facilitating product development for new antibiotics, diagnostic
tests, and vaccines; (2) promoting appropriate use of antibiotics, education, and
other resources; (3) supporting the development of surveillance tools; and (4)
advancing regulatory science.63 To encourage new development, the FDA uses
a variety of tools including fast track designation, priority review, and
breakthrough therapy designation.64 In addition to addressing antibiotic
resistance on humans, the FDA works to promote the appropriate use of
antibiotics in veterinary settings to complement the work of other federal
agencies in healthcare settings.65 As such, in 2003, the FDA established industrywide guidance for assessing antibiotic resistance in the FDA approval process
for animal drugs.66
58. Id.
59. David Hyun & Ariana Olshan, Congress Seeks to Boost Hospital Reporting of Antibiotic Use,
PEW CHARITABLE TRS. (Dec. 20, 2019), https://www.pewtrusts.org/en/research-and-analysis/articles/
2019/12/20/congress-seeks-to-boost-hospital-reporting-of-antibiotic-use.
60. CTRS. FOR DISEASE CONTROL & PREVENTION & CTRS. FOR MEDICARE & MEDICAID SERVS.,
Adherence to the Centers for Disease Control and Prevention’s (CDC’s) Infection Definitions and
Criteria is Needed to Assure Accuracy, Completeness, and Comparability of Infection Control,
https://www.cdc.gov/nhsn/pdfs/cms/NHSN-Reporting-signed.pdf.
61. CDC, THE CORE ELEMENTS, supra note 53, at 20.
62. See Antimicrobial Resistance Information from FDA, FOOD & DRUG ADMIN.,
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistanceinformation-fda (Mar. 2022) (highlighting the FDA’s role and strategic approach to antimicrobial
resistance).
63. Id.
64. Id.
65. Id.; see also FOOD & DRUG AMIN., SUPPORTING ANTIMICROBIAL STEWARDSHIP IN VETERINARY
SETTINGS: GOALS FOR FISCAL YEARS 2019-2023 (2018) (discussing actions being taken by the FDA’s
Center for Veterinary Medicine and other stakeholders to support antimicrobial stewardship in veterinary
settings).
66. Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbial Effects
on Bacteria of Human Health Concern, FOOD & DRUG ADMIN. (Oct. 2003), https://www.fda.gov/
regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobialnew-animal-drugs-regard-their-microbiological-effects; Timeline of FDA Action on Antimicrobial
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D. State and Local Health Departments: Objectives and Activities
Public health has traditionally been a state law objective since it falls under
the scope of states’ police power.67 Generally, the role of State and local
Departments of Health includes screening for diseases, treatment, training
programs, state laboratory services, epidemiology, and surveillance.68 There are
ten essential public health services established by The Core Public Health
Functions Steering Committee in 1994.69 Of these ten services, the most
important for the purposes of this article include: monitoring to address
community health problems, diagnosing and investigating health concerns in the
community, and providing information and education to the public about public
health concerns.70 These essential public health services denote some of the
traditional areas in which state and local health departments have engaged and
deployed their resources.
1. Surveillance, Monitoring, and Educational Activities
Surveillance and monitoring activities have rapidly evolved in a changing
data-driven world, specifically with the rise of public health informatics.71 Public
health surveillance activities are now able to provide scientific data to guide
public health decision-making.72 Surveillance data can “inform policy changes,
guide new proven interventions, sharpen public communication, and help
agencies assess research investments.”73 Surveillance can also act as a warning
system, track progress of goals, and monitor emerging concerns.74 Through the

Resistance, FOOD & DRUG ADMIN. (Jul. 2019), https://www.fda.gov/animal-veterinary/antimicrobialresistance/timeline-fda-action-antimicrobial-resistance.
67. The State Health Department, AM. PUB. HEALTH ASS’N (Jan. 1968), https://www.apha.org/
policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/21/09/50/the-statehealth-department.
68. The State Health Department’s Role in the Policy Process, CTRS. FOR DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/injury/pdfs/shd_policy_tool-a.pdf (last visited Mar. 27, 2022).
69. Public Health Professionals Gateway: 10 Essential Public Health Services, CTRS. FOR DISEASE
CONTROL & PREVENTION, https://www.cdc.gov/publichealthgateway/publichealthservices/essential
healthservices.html (March 18, 2021).
70. Id.
71. PETER NSUBUGA ET AL., DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, CH. 53:
PUBLIC HEALTH SURVEILLANCE: A TOOL FOR TARGETING AND MONITORING INTERVENTIONS 1000 (2d
ed. 2006). “The rapidly evolving field of public health informatics, which deals with collection,
classification, storage, retrieval, analysis, and presentation of large amounts of health data, offers the
potential for truly integrated public health surveillance based on data standardization, a communications
infrastructure, and policies on data access and sharing.” Id.
72. Id. at 998.
73. Public Health Surveillance and Data: Service Through Surveillance, CTRS. FOR DISEASE
CONTROL & PREVENTION (Aug. 24, 2018), https://www.cdc.gov/surveillance/improving-surveillance/
Public-health-surveillance.html.
74. Health Topics: Surveillance in Emergencies, WORLD HEALTH ORG., https://www.who.int/
emergencies/surveillance (last visited Mar. 22, 2022).
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use of new data systems, public health experts can begin to harness and react to
more data than ever before.75 The CDC also provides grants to state and local
health departments to support state and local surveillance activities.76
Another important aspect of state and local health departments is their
educational and community outreach activities. The surveillance and monitoring
activities of the state and local health departments can then lead educational
activities of state and local health departments. Major services of health
departments include professional education and public health education.77 These
educational functions are incredibly important on the state and local levels due
to the close nature of state and local governments to the people.78 An important
extension of these activities with twenty-first century solutions is PDMPs.
E. Existing Prescription Drug Monitoring Infrastructure
PDMPs are state-run electronic databases that track and monitor
prescriptions for controlled substances.79 Currently, all fifty states, the District
of Columbia, Guam, and Puerto Rico have operational PDMPs.80 These
programs were implemented as a way to control the opioid epidemic and alter
prescriber and patient behaviors around opioids.81 Through these programs,
states can “collect, monitor, and analyze . . . data . . . to support states’ efforts in
education, research, enforcement, and abuse prevention.”82 Effective PDMPs
feature four promising elements: (1) universal utilization by prescribers and
pharmacists, (2) real-time data submission by pharmacists, (3) active
management by state health departments, and (4) ease of usage and
accessibility.83

75. See NSUBUGA ET AL., supra note 71, at 997 (explaining that health agencies around the world
have started using data during the COVID-19 pandemic to create better public health outcomes).
76. Public Health Surveillance and Data, supra note 73. “Nearly one third of CDC extramural grant
awards and dollars support surveillance related programs, with the majority of support going to state and
local health departments.” Id.
77. Education & Training Opportunities, U.S. DEPT. OF HEALTH & HUM. SERVS.,
https://www.hhs.gov/programs/education-and-training/index.html (March 27, 2018).
78. HODGE, supra note 33, at 59–62.
79. Opioid Overdose: What States Need to Know, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/drugoverdose/pdmp/index.html (May 19, 2021).
80. PDMP Frequently Asked Questions, PRESCRIPTION DRUG MONITORING PROGRAM, TRAINING &
TECH. ASSISTANCE CTR. (Sept. 2019), https://www.pdmpassist.org/State [hereinafter PDMP, PDMP
Frequently Asked Questions].
81. See Opioid Overdose: What States Need to Know, supra note 79 (noting that improvements have
been made to opioid prescribing by providing data such as patient prescription histories).
82. PRESCRIPTION DRUG MONITORING PROGRAM & TRAINING & TECH. ASSISTANCE CTR.,
PRESCRIPTION DRUG MONITORING PROGRAM AND MEDICAL EXAMINER/CORONER MEETING 1,
https://www.pdmpassist.org/pdf/Resources/PDMP_ME-C_Meeting_Summary_20190703.pdf
(last
visited Mar. 27, 2022) [hereinafter PDMP, MEDICAL EXAMINER/CORONER MEETING].
83. Opioid Overdose: What States Need to Know, supra note 79.
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Currently, PDMPs monitor controlled substances based on the schedules
established by the Federal Controlled Substances Act (CSA).84 Each state has
autonomy in setting up its PDMP program as it sees fit with differences in
various program aspects, such as the time requirements for reporting, who is able
to access the data, and other reporting and use requirements.85 PDMP best
practices include interstate data sharing, integration with health information
exchanges, delegate access, user education, and the timeliness of data.86 From a
public health standpoint, PDMPs can be incredibly useful in the areas of
education, epidemiologic surveillance, prevention, and early intervention.87
Another promising feature of PDMPs is the ability to send unsolicited reports to
prescribers.
1. Unsolicited Reporting Notifications
Unsolicited reporting, a notification to prescribers regarding patients with
high utilization of controlled substances, is considered a PDMP best practice.88
Unsolicited reporting can serve the following important goals: “informing
prescribers and pharmacists that patients may be abusing or diverting controlled
substances; helping prescribers make better decisions about prescribing
controlled substances, thus improving patient care; and informing potential end
users about the PDMP and its value.”89 In the context of PDMPs, most of the
data provided is solicited, meaning that the prescriber must request the
information to see it.90 By providing only solicited data, however, there is a
wealth of helpful information that is potentially not reviewed or acted upon.91 To
provide this useful information and data to prescribers, there must be an

84. PRESCRIPTION DRUG MONITORING PROGRAM & TRAINING & TECH. ASSISTANCE CTR., PDMP
MODEL ACT 2020, at 1, 4 (2020), https://www.pdmpassist.org/pdf/PDMP_Model_Act_2020.pdf
[hereinafter PDMP, MODEL ACT 2020].
85. AM. SOC’Y OF ADDICTION MED., PUBLIC POLICY STATEMENT ON PRESCRIPTION DRUG
MONITORING PROGRAMS (PDMPS) 1 (2018), https://www.asam.org/docs/default-source/public-policystatements/2018-statement-on-pdmpsf406229472bc604ca5b7ff000030b21a.pdf?sfvrsn=63ba42c2_0
[hereinafter ASAM, PRESCRIPTION DRUG MONITORING PROGRAMS].
86. Id.
87. PDMP CTR. OF EXCELLENCE AT BRANDEIS, BRIEFING ON PDMP EFFECTIVENESS 9 (Sept. 2014),
https://dhhs.ne.gov/DOP%20document%20library/PDMP%20Center%20of%20Excellence%20Briefing.
pdf [hereinafter BRIEFING ON PDMP EFFECTIVENESS].
88. PDMP CTR. OF EXCELLENCE AT BRANDEIS, GUIDANCE ON PDMP BEST PRACTICES: OPTIONS
FOR UNSOLICITED REPORTING 4 (2014), https://www.ojp.gov/pdffiles1/bja/247135.pdf/ [hereinafter
GUIDANCE ON PDMP BEST PRACTICES].
89. ASS’N. STATE & TERRITORIAL HEALTH OFFS., PRESCRIPTION DRUG MONITORING PROGRAMS:
TOOLS FOR EDUCATION, EPIDEMIOLOGICAL SURVEILLANCE, PREVENTION, AND EARLY INTERVENTION 4,
http://www.astho.org/Rx/Brandeis-PDMP-Report/.
90. FED’N OF STATE MED. BDS., PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPS): REPORT
AND RECOMMENDATIONS OF THE WORKGROUP ON PDMPS 6 (2018), https://www.fsmb.org/siteassets/
advocacy/policies/prescription-drug-monitoring-programs-adopted.pdf.
91. Id.
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underlying analysis of PDMP data “to identify patients meeting criteria for
possible inappropriate use[s] of controlled substances or for receiving possibly
dangerous quantities and/or combinations of prescription drugs.”92 In unsolicited
reporting, it is important that false positives—which could reduce the
effectiveness of the program—are not over-produced.93 Therefore, a threshold
that would trigger a reporting requirement must be established. Unfortunately,
among the states that utilize unsolicited reporting, no such consensus on a
common threshold has been recognized.94 Unsolicited reporting has been found
to be beneficial, for example, in Maine, where a substantial portion of the
prescribers who received unsolicited reports relating to opioids responded and
acted upon the notification.95
F. Innovative Uses of PDMP and Other Health Information Exchange
Programs
Through the creation of PDMP Programs, various states have also created
innovative uses of the PDMP infrastructure with the integration of other health
data services. Part II.F. highlights two states and their efforts in the health
Information Technology (IT) space: Maryland and Utah.
1. Maryland’s Chesapeake Regional Information System for our Patients
(CRISP)96
Maryland has established a state-wide Health Information Exchange (HIE)
known as “CRISP” which provides a comprehensive, multi-faceted approach to
PDMP and various other health data points.97 CRISP was designated by the
Maryland Health Care Commission as the statewide HIE.98 CRISP seeks to foster
innovative uses of health data throughout the state through “safer, timelier,
efficient, effective, equitable, patient centered care.”99 CRISP includes a variety
of health information services, including:

92. GUIDANCE ON PDMP BEST PRACTICES, supra note 88, at 7.
93. Id. at 7.
94. ASS’N. STATE & TERRITORIAL HEALTH OFFS., supra note 89, at 4.
95. GUIDANCE ON PDMP BEST PRACTICES, supra note 88, at 8.
96. See generally MD. CODE ANN., HEALTH–GEN. § 21-2A-01 et seq. (West 2020) (codifying
Maryland’s PDMP law and outlining its requirements).
97. CRISP, https://crisphealth.org/ (last visited Feb. 2, 2022).
98. PDMP Frequently Asked Questions¸ MD. DEP’T OF HEALTH, https://health.maryland.gov/pdmp/
Pages/-PDMP_FAQs.aspx (last visited Feb. 2, 2022) [hereinafter MD. DEP’T OF HEALTH, PDMP
Frequently Asked Questions].
99. Chesapeake Regional Information System for Our Patients (CRISP), JOHNS HOPKINS INST.
CLINICAL & TRANSITIONAL RSCH., https://ictr.johnshopkins.edu/service/informatics (last visited Mar. 24,
2022).
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(1) Clinical Query Portal, which provides real time clinical
information including labs, radiology reports, operative
reports, and other clinical notes;100
(2) Encounter Notification Service (ENS), which provides realtime alerts to providers when one of their patients is
hospitalized;
(3) PDMP;
(4) Direct Messaging through CRISP DIRECT, which provides
a secure and encrypted e-mail service for health care
providers;
(5) Image Exchange, which provides providers with high-quality
radiograph images;
(6) CRISP Reporting Service, which provides healthcare data
and analytics to improve patient care;101 and
(7) Single Sign-On, which provides integration into medical
office software to access CRISP services.102
The Maryland CRISP system, through these various programs, shares data with
health care providers to facilitate care, reduce costs, and improve health
outcomes.103
The PDMP program is administered by CRISP and is overseen by the
Maryland Department of Health, Behavioral Health Administration.104 The
Maryland PDMP was created to reduce abuse and diversion of prescription
drugs.105 Participation in the Maryland PDMP is mandatory for prescribers and
pharmacists.106
2. Utah’s Health Information and PDMP Infrastructure
Like Maryland’s use of CRISP, Utah has established comprehensive, linked
databases that includes PDMP, All Payer Claims Database, Emergency
Department Encounter, and Hospital Inpatient Discharge, among others.107

100. Clinical Query Portal, CRISP, https://www.crisphealth.org/wp-content/uploads/2016/03/PortalFlyer-Edited-8_16.pdf (last visited Feb. 2, 2022).
101. CRISP Reporting Services, CRISP, https://www.crisphealth.org/applications/crisp-reportingservices-crs/ (last visited Feb. 2, 2022).
102. See For Patients: What is CRISP?, CRISP, https://www.crisphealth.org/for-patients/#what-iscrisp (last visited Feb. 2, 2022) (discussing integration between hospitals and medical professionals to
ease access to clinical information).
103. Id.
104. Maryland Prescription Drug Monitoring Program, MD. DEP’T OF HEALTH, https://health.
maryland.gov/pdmp/Pages/Home.aspx (last visited Feb. 2, 2022).
105. Id.
106. MD. CODE ANN., HEALTH–GEN. § 21-2A-02(c) (West 2019).
107. See COMAGINE HEALTH & UTAH DEPT. OF HEALTH, LEVELS OF CARE FOR TREATING OVERDOSE
AND OPIOID USE DISORDER IN UTAH EMERGENCY DEPARTMENTS AND HOSPITALS 3, 10,13 (2020)
(describing Utah’s efforts to address overdose and opioid use in hospitals). Additional linked data bases
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Utah’s PDMP (also known as the Controlled Substance Database Program)
tracks: morphine milligram equivalents of the patient’s current level of opioid
use,108 the number of pharmacies visited in the last month, and if there are any
overlapping opioid and benzodiazepine prescriptions.109 Additionally, Utah has
established licensure penalties for failure to register with the program.110
Utah also uses a patient review and restriction program (PRR) to encourage
the safe use of opioid prescriptions.111 An individual can be identified as at-risk,
thereby triggering the program, by satisfying one or more of the following
criteria:
(1) Filling six or more abuse-potential medications in a twelvemonth period;
(2) Utilizing four or more pharmacies in a twelve-month period;
(3) Visiting: “[f]our or more nonaffiliated primary care providers
and/or four or more specialists . . . outside a normal range of
utilization in a 12-month period, and/or three or more
nonaffiliated
providers
prescribing
abuse-potential
medications in a 12-month period”;
(4) Having “five or more nonemergent emergency department
visits in 12-months”;
(5) Providing cash payments for prescriptions;
(6) Exhibiting “patterns of early refills or attempted early refills
for abuse-potential medications”; or
(7) Providing “concurrent prescriptions of abuse-potential
medications written by nonaffiliated prescribers.”112
Once a PRR is triggered, patients are required to receive controlled substances
from a designated prescriber and pharmacist.113

include a cancer registry, death and medical examiner reports, the national violent death reporting system,
and data relating to continuing medical education completion. Id.
108. Morphine Milligram equivalents (MMEs) are “[t]he amount of milligrams of morphine an opioid
dosage is equal to when prescribed.” OFF. OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUM. SERVS.,
FACTSHEET: UTAH’S OVERSIGHT OF OPIOID PRESCRIBING AND MONITORING OF OPIOID USE 14 (2019),
https://oig.hhs.gov/oas/reports/region7/71805115_Factsheet.pdf/.
109. Id. at 6.
110. UTAH CODE ANN. § 58-37f-401(4) (West 2018). These licensure actions include refusing to issue
a license, refusing to renew a license, or revocation, suspension, or restriction of an individual’s license.
Id.
111. PEW CHARITABLE TRS., MEDICAID PROGRAMS THAT IMPROVE THE SAFETY OF OPIOID USE:
SPOTLIGHT ON UTAH 1 (2016), https://www.pewtrusts.org/-/media/assets/2016/09/pda_rxastateutah
_factsheet-final_updated_927.pdf?la=en&hash=40DD664FF960E5E5FBD59B6B1F2DF641EB1EEE79
[hereinafter PEW CHARITABLE TRS., SPOTLIGHT ON UTAH].
112. Id.; see also Restriction Program, UTAH DEP’T. OF HEALTH: MEDICAID, https://medicaid.utah.
gov/restriction-program/ (last visited Feb. 2, 2022) (describing prescription restriction requirements for
Medicaid enrollees in Utah).
113. PEW CHARITABLE TRS., SPOTLIGHT ON UTAH, supra note 111, at 1.
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Utah also maintains the Utah Health Information Network (UHIN) which
operates the Clinical Health Information Exchange (CHIE).114 The CHIE
includes various features such as:
(1) CHIE Alerts, which provides a notification when patients are
admitted or discharged from a hospital or emergency
department;
(2) Direct Secure Messaging, which allows secure
communications between healthcare professionals;
(3) Results Delivery, which provides laboratory, radiology,
clinical notes, poison control, and EMS reports; and
(4) Historical Look-backs, which are triggered when a patient is
admitted, discharged, or transferred from a hospital or
emergency department and provide an overview the patients
previous admissions.115
UHIN works toward securely harnessing healthcare data to create innovative
software solutions for the healthcare community.116
III. LEVERAGING PDMPS FOR ANTIBIOTIC TRACKING
This article, while applauding the work that the CDC and other
governmental agencies have done, suggests a new state surveillance and
education program using the existing PDMP infrastructure. Managing and
utilizing state PDMP infrastructure is beneficial since “[s]tates tend to have
closer connections to the problems they regulate, which allow them to adapt to
local conditions and to improve both compliance and enforcement.”117 States
also have authority to regulate in this area.118 Part III.A. begins with a theoretical
approach on how surveillance programs could be deployed through PDMP
programs.119 Then, Part III.B. discusses the legal approach to implement such a
program considering federal and state level requirements.120

114. The CHIE: Clinical Health Information for Providers, UTAH HEALTH INFO. NETWORK,
https://uhin.org/solutions/providers/chie-providers/ (last visited Feb. 2, 2022).
115. Id.
116. About Us, UTAH HEALTH INFO. NETWORK, https://uhin.org/about/ (last visited Feb. 2, 2022).
117. William M. Sage & David A. Hyman, Combatting Antimicrobial Resistance: Regulatory
Strategies and Institutional Capacity, 84 TUL. L. REV. 781, 833 (2010).
118. See Strategies and Partnerships, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/drugoverdose/policy/index.html (Apr. 20, 2021) (describing steps states can take to
prevent overdoses, including implementing specific laws and improving practices for state programs like
Medicaid and worker’s compensation).
119. See infra Part III.A.
120. See infra Part III.B.
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A. Surveillance Programs Through the Use of PDMP
This proposal seeks to broaden the surveillance ability of state and local
health departments by expanding upon the existing infrastructure of PDMPs.
Since all states and the District of Columbia have existing PDMP programs, the
infrastructure for establishing this kind of antibiotic surveillance is already in
place.121 Currently, PDMPs are administered by various state agencies including
pharmacy boards, departments of health, professional licensing agencies, law
enforcement agencies, and substance abuse agencies.122 Various states also track
information through their PDMP that is not specific to controlled substance
prescribing including: drug-related arrests, drug-related convictions, child
welfare case information, criminal court case information, drug court case
information, medical marijuana dispensing, naloxone prescription/
administration, and overdoses.123 The integration of this additional information
within the PDMP software demonstrates the feasibility of extending this software
to include antibiotic related prescriptions and data.
Interestingly, one state, Nebraska, currently monitors all prescription drugs
through their PDMP.124 On January 1, 2018, Nebraska began monitoring all
dispensed prescriptions so that clinicians could better monitor the care and
treatment of their patients.125 The shift towards tracking all prescriptions in
Nebraska was focused on patient safety and the need for accurate medication
reconciliation.126 The Nebraska PDMP allows prescribers and dispensers to sort
through controlled and non-controlled prescriptions.127 Nebraska’s
comprehensive PDMP provides “10 x more data than traditional PDMP’s that
include controlled substances only.”128 Upon implementation from January 1
through June 30, 2018, there were 15,795,016 dispensed prescriptions—90% of
these were non-controlled substances.129 The enabling statute, while not

121. State PDMP Profiles and Contacts, PRESCRIPTION DRUG MONITORING PROGRAM & TRAINING
& TECH. ASSISTANCE CTR., https://www.pdmpassist.org/State (last visited Feb. 3, 2022).
122. Id.
123. See DEPT. OF JUST., BUREAU OF JUST. ASSISTANCE, JUSTICE SYSTEM USE OF PRESCRIPTION
DRUG MONITORING PROGRAMS 8–9 (2015) (discussing the intersection between PDMP programs and the
criminal justice system).
124. NEB. REV. STAT. § 71-2454(2) (2020).
125. Berie Monegain, Nebraska Becomes First State to Require All Drugs be Reported to Prescription
Monitoring Program, HEALTHCARE IT NEWS (Jan. 31, 2018, 12:32 PM) https://www.healthcareitnews
.com/news/nebraska-becomes-first-state-require-all-drugs-be-reported-prescription-monitoring-program.
126. Rachel Balick, Nebraska Pharmacists Will Report All Prescriptions to State PDMP, PHARMACY
TODAY, Nov. 1, 2017, at 50, 50 https://www.pharmacytoday.org/article/S1042-0991(17)31645-6/fulltext.
127. See id. (explaining that a new law in Nebraska will compel dispensers to report to the State’s
PDMP both controlled and non-controlled prescriptions).
128. Alice Middleton & Kevin Borcher, Nebraska PDMP Case Study, THE HILLTOP INST., 22 (Aug.
2, 2018) https://mhcc.maryland.gov/mhcc/pages/home/workgroups/documents/electronic_prescription/
Nebraska%20Slides_20180802.pdf.
129. Id. at 23.
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specifically focusing on antibiotics, states a purpose of “allowing prescribers and
dispensers to . . . ensure that the prescription drugs are used for medically
appropriate purposes.”130 Nebraska has gone above and beyond the data
requirements advocated for in this article, but for full effectiveness of this
proposal, the data also must be acted upon.
1. Establishing a Surveillance Threshold
Since the infrastructure necessary for PDMPs to track antibiotic
prescriptions is already in place, the hurdle will be in programming the data tool
to identify significant information. To clear this hurdle, a threshold—which will
identify the information that is significant enough to trigger an additional review
by an expert within the Department of Health—must be established.131 As with
the original PDMP infrastructure, parallels can be made between opioids and the
thresholds established for unsolicited reports and PRRs. Upon discussion of
these parallels, the following Part concludes with suggested features of a
threshold that would be best suited to combat antibiotic resistance.132
a. Parallels to Opioids with Unsolicited Reports
Unsolicited reports can provide prescribers with important, clinically
relevant information.133 To send an unsolicited report, the PDMP data must be
programmed to identify specific criteria that is suspect of inappropriate use of
controlled substances.134 Criteria can include actions such as: receiving
prescriptions of the same drug type from multiple prescribers or multiple
pharmacies in a relatively short period of time, being prescribed higher than a
certain number of morphine milligram equivalents, and receiving prescriptions
for opioids and benzodiazepines.135 For instance, Maine’s regulatory
requirements for PDMP-related unsolicited reporting provide that threshold
levels may include, but are not limited to, any of the following:
• High number of prescribers in a short period of time as
determined by the office;
• High number of doses during a short period of time, as
determined by the office;
• Days Supply of prescriptions for the same drug overlapping
by more than a few days;

130. NEB. REV. STAT. § 71-2454(1) (2011).
131. See supra text accompanying notes 121–123.
132. See infra Part III.A.1.a.
133. See GUIDANCE ON PDMP BEST PRACTICES, supra note 88, at 5 (“A growing body of evidence
supports unsolicited reporting as a PDMP best practice.”).
134. Id. at 7.
135. Id.
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•

Inappropriate combinations of controlled substances, as
determined by the Office;
• More than one method of payment within a short time period;
• More than one out of state prescriber for the same patient,
during a short time period, as determined by the Office;
• More than one pharmacy in the same day; or
• More than one pharmacy in different public health districts
within one month; and/or Dangerous levels of specific drugs,
as determined by the office.136
As of April 2022, thirty-seven jurisdictions had PDMP systems that provided
unsolicited reports to prescribers,137 and twenty-six jurisdictions had PDMP
systems that sent unsolicited reports to dispensers.138 Among these jurisdictions,
there is no consensus as to what triggers a report.139 Therefore, in the context of
antibiotics, it is important to establish a threshold at which review would be
triggered in the State Department of Health for high utilization patients and
providers.
b. Parallels to Opioids and PRRs
Also in the context of opioids, PRRs are widely used by Medicaid plans
and commercial insurers.140 Forty-nine state Medicaid plans operate PRRs; Utah
is one such jurisdiction.141 These programs, once identifying a patient, restrict
their access to controlled substances by limiting their ability to procure controlled
substances to a single designated prescriber, pharmacy, or both.142 The criteria
used is largely up to the state’s discretion and “var[ies] from [a] simple numeric
threshold to an extensive list of criteria that includes a wide variety of behaviors
indicative of over-utilization or fraud.”143 The intent of these programs is to

136. 14-118-11 ME. CODE R. § 9 (2) (LexisNexis 2022). Additionally, upon meeting this threshold,
the prescriber and dispenser is notified. Id.
137. PRESCRIPTION DRUG MONITORING PROGRAM & TRAINING & TECH. ASSISTANCE CTR., PDMPS
AUTHORIZED AND ENGAGED IN SENDING SOLICITED AND UNSOLICITED REPORTS TO HEALTH CARE
PROVIDERS AND PATIENTS (2020), https://www.pdmpassist.org/pdf/Health_Care_Entity_Table.pdf
[hereinafter PDMP, SOLICITED AND UNSOLICITED REPORTS].
138. Id.
139. ASS’N. STATE & TERRITORIAL HEALTH OFFS., supra note 89, at 4.
140. Examining the Opioid Epidemic: Challenges and Opportunities: Hearing Before the S. Comm.
of Fin., 114th Cong. 2 (2016) (statement of Allan Couckell, Senior Director, Health Programs, The Pew
Charitable Trusts).
141. Id.; see also supra Part II.F.2 (explaining Utah’s PRR program).
142. AM. SOC’Y OF ADDICTION MED., PUBLIC POLICY STATEMENT ON PATIENT REVIEW AND
RESTRICTION (PRR) PROGRAMS 1 (2016), https://www.asam.org/docs/default-source/public-policystatements/11-2-public-policy-statement-on-prr-programs—-updated.pdf?sfvrsn=5b5d74c2_0
[hereinafter ASAM, PATIENT REVIEW AND RESTRICTION (PRR) PROGRAMS].
143. CTRS. FOR DISEASE CONTROL & PREVENTION, PATIENT REVIEW & RESTRICTION PROGRAMS:
LESSONS LEARNED FROM STATE MEDICAID PROGRAMS 3 (2012), https://www.cdc.gov/drugoverdose/pdf/
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identify those who are at risk of an overdose—based on certain established
factors—and ensure that they receive care coordination.144
c. Suggested Features of a Threshold
While “doctor shopping”145 is less of a concern with antibiotic prescriptions
(than with opioids or other controlled substances), monitoring and surveillance
is still essential. As previously demonstrated, not all PDMPs are alike.146 Thus,
it would likely be difficult to achieve a uniform threshold. Nevertheless,
suggestions can be made through model legislation.147 Model legislation has
been used in the field of public health as early as 1907.148 In this context, model
legislation should be proposed to create a threshold for triggering review. Using
opioids as guidance, the following factors should be considered in the threshold:
(1) Use of a certain number of antibiotics within a twelve-month
period;
(2) Multiple antibiotic prescriptions by multiple prescribers;
(3) Use of two or more antibiotics on the WHO’s watch list149 in
a six-month period; and
(4) Use of any antibiotic which is on the WHO’s reserve list.150
While it would be challenging to establish a threshold to determine when a
particular prescriber is overprescribing, a simple numerical analysis could be
conducted to identify the highest prescribers. This identification could then
trigger a review which considers other factors such as the prescriber’s specialty
and the number of patients he or she typically services. Providers in certain
specialties will ultimately produce more antibiotic prescriptions than others
simply because of their chosen specialty. However, these providers could be
compared to other providers within the same specialty to compare utilization.

PDO_patient_review_meeting-a.pdf [hereinafter CDC, LESSONS LEARNED FROM STATE MEDICAID
PROGRAMS].
144. Examining the Opioid Epidemic: Challenges and Opportunities, supra note 140, at 2.
145. “Doctor shopping” generally refers to “a patient obtaining controlled substances from multiple
healthcare practitioners without the prescribers knowledge.” CTRS. FOR DISEASE CONTROL &
PREVENTION, PUBLIC HEALTH LAW: DOCTOR SHOPPING LAWS 1 (2012), https://www.cdc.gov/phlp/docs/
menu-shoppinglaws.pdf [hereinafter CDC, DOCTOR SHOPPING LAWS].
146. See generally Maps and Tables, PRESCRIPTION DRUG MONITORING PROGRAM & TRAINING &
TECH. ASSISTANCE CTR., https://www.pdmpassist.org/content/pdmp-maps-and-tables (last visited March
2, 2022) [hereinafter PDMP, Maps and Tables] (displaying and summarizing PDMPs in different states).
147. Various organizations provide model state legislation on a variety of topics. See, e.g., About
Shared State Legislation, COUNCIL OF STATE GOV’TS., https://ssl.csg.org/about/ (sharing state legislation
among different states); see also Current Docket, AM. ACAD. OF FAM. PHYSICIANS, https://ssl.csg.org/
current-docket/ (presenting model legislation on a variety of topics.).
148. DeKeely Hartsfield et al., A Review of Model Public Health Laws, 97 AM. J. PUB. HEALTH. S56,
S56 (2007).
149. WORLD HEALTH ORG., supra note 13, at 3.
150. Id. at 4.
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B. Legal Approach
As is evident from the varying natures of PMDP programs across the
country, the legal approach to establishing this sort of monitoring system will
require a state level legislative approach.151 Nevertheless, federalism requires
both federal and state considerations.
1. Federal Level Considerations
The major federal consideration is what sort of support the federal
government would be willing to provide to states looking to establish antibiotic
tracking programs through PDMP. Since 2016, the CDC AR Solutions Initiative
has provided “$241 million to 57 state and local health departments.”152
Moreover, federal grants were essential to the original creation of PDMPs
through the Harold Rogers PDMP Grant Program administered by the Federal
Department of Justice’s Bureau of Justice Assistance.153 Since most current
federal grants for PDMPs involve substance abuse monitoring, different
considerations would arise if federal grants were to be extended to PDMPs for
antibiotic resistance and tracking. Another potential federal approach would be
to reschedule all antibiotics or certain high-risk antibiotics as Schedule V
Substances under the CSA.154 This could, however, potentially require states to
begin tracking antibiotics without state initiative since many state PDMPs track
prescriptions based on the Federal Controlled and Dangerous Substances
schedule.
2. State Level Considerations
At the state level, there will be three major policy considerations when
developing a program for tracking and monitoring antibiotic prescriptions. These
considerations include: (1) amending existing PDMP laws; (2) establishing
thresholds to trigger review by the state health department; and (3) observing
federal and state privacy laws.

151. See PDMP, Maps and Tables, supra note 146 (displaying the varying nature of different PDMP
programs in different states).
152. CTRS. FOR DISEASE CONTROL & PREVENTION, ACTIONS TO COMBAT ANTIBIOTIC RESISTANCE
(AR), FISCAL YEAR 2016-2019, https://www.cdc.gov/drugresistance/pdf/threats-report/CDC-ActionsCombat-AR-508.pdf [hereinafter CDC, ACTIONS TO COMBAT ANTIBIOTIC RESISTANCE].
153. U.S. DEP’T OF JUST., HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM FY 2013
COMPETITIVE GRANT ANNOUNCEMENT 1 (2013), https://bja.ojp.gov/sites/g/files/xyckuh186/files/media/
document/BJA-2013-3526.pdf.
154. Currently eleven jurisdictions only monitor Schedules II-IV, which would mean reclassifying
antibiotics into Schedule V would not be tracked in these eleven jurisdictions. PRESCRIPTION DRUG
MONITORING PROGRAM & TRAINING & TECH. ASSISTANCE CTR., MANDATORY PDMP ENROLLMENT
(2022), https://www.pdmpassist.org/pdf/Mandatory_Enrollment_Conditions.pdf [hereinafter PDMP,
MANDATORY PDMP ENROLLMENT].
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Since states already have existing PDMPs the authorizing legislation must
be amended to include the provision of antibiotics.155 Alternatively, states could
take Nebraska’s approach and include all prescription medications. To address
these amendments, a state would require support from both chambers of its
legislature. Additionally, law and policy concerning the threshold requirement
could be established through the legislative process or through agency
regulations. Moreover, state legislatures would need to consider federal and state
privacy protections, which most PDMPs already include protections for; current
PDMP statutes include privacy clauses and penalties for violations of
confidentiality.156 These protections will likely remain if existing PDMP laws
are simply amended. Therefore, in order to address these concerns, legislatures
would need to ensure that the existing protections apply when amendments are
made to include antibiotic tracking.
IV. CONCLUSION
In the age of big data, as antibiotic resistance is growing, it is important to
consider the data analytics tools we already have at our fingertips. Through
legislative changes to existing PDMP statutes, states could begin tracking their
antibiotic prescriptions to anticipate emerging microbial concerns and trends.
These new tracking and monitoring programs could allow public health experts
to turn the tides in terms of antibiotic resistance. Antibiotics present a paradox:
while antibiotic-use is necessary to treat certain illnesses, every use can cause
bacteria to evolve, rendering that antibiotic essentially useless.157 Tracking is a
core element of antibiotic stewardship, as defined by the CDC.158 Through the
use of tracking, monitoring and surveillance, state health departments can begin
to combat antibiotic resistance within their jurisdictions.

155. See PDMP, Maps and Tables, supra note 146 (explaining State PDMP programs).
156. MD. CODE ANN., HEALTH–GEN. § 21-2A-04 (b)(9)(i-ii) (West 2019).
157. See LaMontagne, supra note 20, at 301 (explaining that the use of antibiotics can create antibiotic
resistant bacteria).
158. CDC, THE CORE ELEMENTS, supra note 53, at 15.

